Satiasolv is a product containing cannabidiol, an active phytocannabinoid derived of Cannabis sativa. It is one of at least 85 active cannabinoids identified in the plant.
CBD interacts with the body‘s endocannabinoid system (ECS), which plays a key role in regulating sleep, mood, pain sensation, inflammation, and immune responses.
Solubility of highly active compounds is the key factor for efficient medical use. CBD is a hardly soluble and highly lipophilic API, classified as BCS class II drug of the Biopharmaceutics Classification System. Based on the proprietary Marinosolv® solubilizazion technology, Satiasolv allows for previously unavailable dosage options.
A preclinical intranasal delivery model shows that cannabidiol formulated with Marinosolv® achieves significantly higher brain uptake compared to a marketed oil-based reference product - despite a 100-fold lower API concentration.
These findings highlight the potential of the Marinosolv® technology for targeted delivery of lipophilic drugs via the nasal route - particularly to central sites of action such as the brain.
Marinosolv® makes hydrophobic drugs soluble and effective - right where they are needed.
